2 weeks Ago By ABMN Staff
Texas Permanent School Fund Corp boosted its holdings in Corcept Therapeutics Incorporated ( NASDAQ:CORT – Free Report ) by 3.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 82,287 shares of the biotechnology company’s stock after acquiring an additional 2,897 shares during the quarter.
Texas Permanent School Fund Corp’s holdings in Corcept Therapeutics were worth $2,674,000 as of its most recent filing with the SEC. Other large investors have also recently bought and sold shares of the company. Park Place Capital Corp purchased a new position in Corcept Therapeutics in the second quarter worth $32,000.
Atwood & Palmer Inc. purchased a new position in shares of Corcept Therapeutics in the second quarter valued at $35,000. GAMMA Investing LLC increased its position in shares of Corcept Therapeutics by 90.
6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 579 shares in the last quarter. FinTrust Capital Advisors LLC increased its position in shares of Corcept Therapeutics by 318.
7% in the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 1,348 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in shares of Corcept Therapeutics by 27.
0% in the fourth quarter. Quadrant Capital Group LLC now owns 2,107 shares of the biotechnology company’s stock valued at $68,000 after buying an additional 448 shares in the last quarter. Hedge funds and other institutional investors own 93.
61% of the company’s stock. Wall Street Analyst Weigh In A number of research firms recently commented on CORT. Piper Sandler increased their price objective on Corcept Therapeutics from $35.
00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. HC Wainwright increased their price objective on Corcept Therapeutics from $40.
00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $38.
00 price objective on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. Finally, Truist Financial reaffirmed a “buy” rating and set a $65.00 price objective on shares of Corcept Therapeutics in a research note on Monday, June 17th.
Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics presently has an average rating of “Buy” and an average target price of $46.50.
Insiders Place Their Bets In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Monday, July 1st.
The stock was sold at an average price of $32.81, for a total value of $72,182.00.
The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . In other news, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $35.
30, for a total value of $353,000.00. Following the transaction, the insider now directly owns 6,039 shares of the company’s stock, valued at approximately $213,176.
70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, Director Daniel N.
Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $32.
81, for a total value of $72,182.00. The disclosure for this sale can be found here .
In the last ninety days, insiders have sold 30,451 shares of company stock valued at $1,090,844. Insiders own 20.50% of the company’s stock.
Corcept Therapeutics Trading Up 0.9 % Shares of NASDAQ:CORT opened at $38.47 on Tuesday.
The stock’s 50-day moving average price is $34.36 and its two-hundred day moving average price is $29.48.
Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $39.75.
The firm has a market cap of $4.01 billion, a price-to-earnings ratio of 36.29 and a beta of 0.
45. Corcept Therapeutics ( NASDAQ:CORT – Get Free Report ) last issued its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.
32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09.
Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%.
The firm had revenue of $163.80 million for the quarter, compared to analyst estimates of $155.14 million.
During the same period last year, the company earned $0.25 EPS. The firm’s quarterly revenue was up 39.
1% on a year-over-year basis. As a group, research analysts forecast that Corcept Therapeutics Incorporated will post 1.1 earnings per share for the current fiscal year.
Corcept Therapeutics Profile ( Free Report ) Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Read More Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated ( NASDAQ:CORT – Free Report ). Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
